Michael S. Rosol
2022
In 2022, Michael S. Rosol earned a total compensation of $429.8K as Chief Medical Officer Principal Executive Officer at Navidea Biopharmaceuticals, a 8% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $81,250 |
|---|---|
| Salary | $336,667 |
| Stock Awards | $3,640 |
| Other | $8,231 |
| Total | $429,788 |
Rosol received $336.7K in salary, accounting for 78% of the total pay in 2022.
Rosol also received $81.3K in non-equity incentive plan, $3.6K in stock awards and $8.2K in other compensation.
Rankings
In 2022, Michael S. Rosol's compensation ranked 4,589th out of 5,753 executives tracked by ExecPay. In other words, Rosol earned more than 20.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,589 out of 5,753 | 20th |
Division Manufacturing | 2,568 out of 3,133 | 18th |
Major group Chemicals And Allied Products | 1,225 out of 1,419 | 14th |
Industry group Drugs | 1,151 out of 1,320 | 13th |
Industry In Vitro and In Vivo Diagnostic Substances | 19 out of 29 | 35th |
Source: SEC filing on October 5, 2023.
Rosol's colleagues
We found one more compensation record of an executive who worked with Michael S. Rosol at Navidea Biopharmaceuticals in 2022.
2022
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019